Effects of turmeric (Curcuma longa) supplementation on glucose metabolism in diabetes mellitus and metabolic syndrome: An umbrella review and updated meta-analysis

Abstract

Aims This study aims to comprehensively review the existing evidence and conduct analysis of updated randomized controlled trials (RCTs) of turmeric (Curcuma longa, CL) and its related bioactive compounds on glycemic and metabolic parameters in patients with type 2 diabetes (T2DM), prediabetes, and metabolic syndrome (MetS) together with a sub-group analysis of different CL preparation forms. Methods An umbrella review (UR) and updated systematic reviews and meta-analyses (SRMAs) were conducted to evaluate the effects of CL compared with a placebo/standard treatment in adult T2DM, prediabetes, and MetS. The MEDLINE, Embase, The Cochrane Central Register of Control Trials, and Scopus databases were searched from inception to September 2022. The primary efficacy outcomes were hemoglobin A1C (HbA1C) and fasting blood glucose (FBG). The corrected covered area (CCA) was used to assess overlap. Mean differences were pooled across individual RCTs using a random-effects model. Subgroup and sensitivity analyses were performed for various CL preparation forms. Results Fourteen SRMAs of 61 individual RCTs were included in the UR. The updated SRMA included 28 studies. The CCA was 11.54%, indicating high overlap across SRMAs. The updated SRMA revealed significant reduction in FBG and HbA1C with CL supplementation, obtaining a mean difference (95% confidence interval [CI]) of –8.129 (–12.175, –4.084) mg/dL and –0.134 (–0.304, –0.037) %, respectively. FBG and HbA1C levels decreased with all CL preparation forms as did other metabolic parameters levels. The results of the sensitivity and subgroup analyses were consistent with those of the main analysis. Conclusion CL supplementation can significantly reduce FBG and HbA1C levels and other metabolic parameters in T2DM and mitigate related conditions, including prediabetes and MetS. Trial registration PROSPERO (CRD42016042131).

<i>Curcuma Longa</i> (Turmeric) Supplements Improved Fasting Blood Glucose Level and Anxiety-Like Behavior in Diabetic Wistar Rats

“…The results may be attributed to the antihyperglycaemic property of C. longa, its antioxidant and anti-inflammatory properties. Poor glycaemic control, oxidative stress, dyslipidemia and inflammation have been linked to anxiety-like behavior and C. longa might have acted through its effect on blood glucose levels, antioxidant enzyme activities, inflammation and dyslipidemia (Ahmad et al, 2020;Sharifi-Rad et al, 2020;Ovaditya et al, 2022;Pathomwichaiwat et al, 2023). These findings disagree with our previous findings where a high percentage (20% C. longa supplementation) increases anxiety-like behavior in normoglycaemic animals (Garkuwa et al, 2021).…”

“…It was shown to improve glucose metabolism (Uchio et al, 2022), reduce fasting blood glucose levels (Pathomwichaiwat et al, 2023), glycaemic control and reduce the formation of advanced glycation end products among type-2 diabetic individuals (Abbas et al, 2022). Hyperglycemia has been the major driver of oxidative stress, inflammation and dyslipidemia (Hasheminasabgorji and Jha, 2021;Tangvarasittichai, 2015).…”

“…Curcuma longa has been previously studied in the form of rhizome extract; it can be efficacious in reducing several parameters in DM patients (Chuengsamarn et al, 2012;Pivari et al, 2019). Also, C. longa rhizome extract caused a decrease in fasting blood glucose levels and glycated hemoglobin in humans (Pathomwichaiwat et al, 2023). However, only a few researches focus on its influence on anxiety-like behavior in diabetic rats.…”

Modification of Polyethylene Glycol-Hydroxypropyl Methacrylate Polymeric Micelles Loaded with Curcumin for Cellular Internalization and Cytotoxicity to Wilms Tumor 1-Expressing Myeloblastic Leukemia K562 Cells

“…PEG-HPMA-DL and PEG-HPMA-Bz were synthesized and characterized using 1 H NMR spectroscopy and gel permeation chromatography as described previously [33]. The 1 H NMR spectra were recorded using a Gemini 300 MHz spectrometer (Varian Associates Inc. NMR Instruments, Palo Alto, CA, USA), using d 6 -DMSO as a solvent and the DMSO peak at 2.50 ppm was used as the reference line. Gel permeation chromatography was performed using two serial PLgel 5 µm MIXED-D columns (Polymer Laboratories).…”

“…Many reports have shown that curcumin possesses anti-diabetic activity [5]. Curcumin supplementation can significantly reduce fasting blood glucose and hemoglobin A1C levels and other metabolic parameters in type 2 diabetes [6,7]. An in vitro study on cancer cell lines demonstrated that curcumin can inhibit cell-cycle progression and metastasis through many signaling pathways [8].…”